SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands							1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 27, 2023 USD ($)	Aug. 29, 2022	Jul. 02, 2021 USD ($) $ / shares shares	May 13, 2021 USD ($)	Jul. 23, 2018 USD ($)	Oct. 19, 2017 USD ($)	Oct. 31, 2015	Sep. 30, 2023 USD ($) agreement $ / shares shares	Mar. 31, 2023 USD ($) shares	Sep. 30, 2023 USD ($) agreement $ / shares shares	Sep. 30, 2022 USD ($)	Mar. 21, 2023 item	Dec. 31, 2022 $ / shares
Significant Accounting Policies [Line Items]
Number of global licensing and supply agreements | agreement								2		2
Number of patients dosed | item												32
Common Stock, Par or Stated Value Per Share | $ / shares								$ 0.001		$ 0.001			$ 0.001
Stock issuance proceeds										$ 23,954	$ 4,161
Convertible Debt, Current								$ 20,192		20,192
ATM Shares
Significant Accounting Policies [Line Items]
Number of shares issued (in shares) | shares									13,980,060
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.001
Sale of stock, maximum offering price	$ 20,000		$ 20,000							$ 6,400
Stock issuance proceeds									$ 20,000
ATM Equity Offering Sales Agreement
Significant Accounting Policies [Line Items]
Number of shares issued (in shares) | shares			3,296,123					0		12,560,150
Stock issuance proceeds			$ 13,800							$ 24,900
2024 Notes
Significant Accounting Policies [Line Items]
Interest rate (as a percent)								7.50%		7.50%
Maintain of Minimum Cash Balance								$ 7,500		$ 7,500
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues and Expenses Sharing Percentage							100.00%
Chiesi Agreements
Significant Accounting Policies [Line Items]
Amount of milestone payment received										$ 20,000
Revenue, Performance Obligation, Number | agreement								2		2
Chiesi US Agreement
Significant Accounting Policies [Line Items]
Additional Amounts Payable To Cover Development Costs					$ 20,000
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones					$ 760,000
Chiesi US Agreement | Minimum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage					15.00%
Chiesi US Agreement | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage					40.00%
Chiesi Ex-US Agreement
Significant Accounting Policies [Line Items]
Additional Amounts Payable To Cover Development Costs						$ 25,000
Agreement Amendment Payment Receivable				$ 10,000
Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones				$ 25,000
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones						$ 320,000
Chiesi Ex-US Agreement | Minimum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage						15.00%
Chiesi Ex-US Agreement | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage						35.00%
Fill/Finish Agreement
Significant Accounting Policies [Line Items]
Extended term of agreement		7 years
Chiesi US Agreement and Chiesi Ex-US Agreement
Significant Accounting Policies [Line Items]
Non-refundable Payment Receivable					$ 25,000	$ 25,000